Skip to main content

Fondsfinans Global Helse

Fondsfinans Global Helse is an equity fund managed by Fondsfinans in the Sektor – Helse category.

About this fund

Fondsfinans Global Helse is an equity fund run by Fondsfinans, compared against the Sektor – Helse peer group.

Launched in 2000, it has 26 years behind it.

On return so far this year measured in NOK as of 13.11.2026, it places 3 of 18 funds in the group.

Tracking error against its benchmark is 4.3%.

The fund has been in Preben Bang's hands since 2022 — 4 years.

The manager states a volatility of 14.5% for the fund.

Manager
Fondsfinans
Category
Sektor – Helse
Region
Global
Sector
Health Care
Style
Sector Focus
SFDR
Article 8
ISIN
NO0010047194
Inception
2000-06-27
AUM
608 m NOK
Returns
YTD 15.7% · 1Y 19.2% · 3Y 8.1% · 5Y 7.4%

Portfolio managers

Actively managedEquityGlobalHealth care
YTD Return · NOK
+15,7 %
NOK class A
Last NAV 74 024,74 NOK · 13 Nov 2026
Returns by period · NOK · net
ann. 3Y+
+15,7 %
YTD
+19,2 %
1y
+8,1 %
3y, annualised
+7,4 %
5y, annualised
+9,1 %
10y, annualised
Fund size
608,2 mill. NOK
Total fund AUM
Management fee
1,00 %
Annual · class A · 0,70 %–1,00 % across 2 share classes
Ongoing charge
1,00 %
Annual · class A
Performance fee
10%
of the excess return
Annual cost on platforms
0,96 %–1,01 %
Class B · 6 platforms · net of platform rebate, incl. platform fee, excl. transaction costs
SFDR
Article 8
Sustainability
Launched
Jun 2000
ISIN NO0010047194
BenchmarkNo benchmark
Fund website
Risk
Volatility (stated by the manager)14,5 %
Sharpe Ratio0,19
Beta0,96
Info Ratio−0,16
Tracking Error4,3 %
About the fund
The fund

Fondsfinans Global Helse is an actively managed global equity fund with history going back to 2000. Its management company, Fondsfinans Kapitalforvaltning, is an Oslo-based manager established as a separate asset management business in 1997 and wholly owned by MUST AS.

Investment philosophy

The mandate limits the fund to large, liquid listed companies in pharmaceuticals, biotechnology, medical equipment and services. The objective is risk-adjusted return, and risk awareness recurs across the team's other funds.

The managers

Preben Bang manages the fund from Oslo and has done so since 2022. He is mentioned together with Melanie Brooks and Fredrik Aarum as a management team. Bang holds a master's degree in physics and mathematics, is a CFA charterholder and certified interest rate analyst, and has a background in risk management and quantitative analysis at NBIM. He also manages Fondsfinans Global Utbytte and Fondsfinans Aktiv 60/40.

The portfolio

The portfolio has a lasting emphasis on pharmaceuticals and biotechnology, with large companies such as Roche, Johnson & Johnson and Eli Lilly among the steady top holdings. The fund has fluctuated less than comparable funds.

FundTelligence description · 18/10/2026
Comparison basis: Ranked among 18 of 31 funds · 13 left out (5 share class outside the rule, 3 missing return, 1 return as of an earlier date, 1 history too short, 3 return without a stated date) · returns as of 12 Nov 2026–13 Nov 2026

Portfolio managers

PR
Portfolio Manager
On the fund since Jan 1, 2022
FR
Medforvalter
On the fund since Jan 1, 2022
ME
Medforvalter
On the fund since Jan 1, 2022

Position in the peer group

Sector Health Care Equities · 31 funds in the peer group. The number ranked and the date are stated per period. 12 of them converted to NOK.

7 of 18 funds ranked on a calculated return

#3/ 18Year to date
+15.71% NOK

as of 13 Nov 2026 · NOK class

About the figures

13 of 31 funds in the group hold no figure for the date and are not counted. 1 funds with older figures: up to 5 business days.

#3/ 221 year
+19.23% NOK

as of 13 Nov 2026 · NOK class

About the figures

9 of 31 funds in the group hold no figure for the date and are not counted. 1 funds with older figures: up to 5 business days.

#9/ 223 years (ann.)
+8.06% NOK

as of 13 Nov 2026 · NOK class

About the figures

9 of 31 funds in the group hold no figure for the date and are not counted. 1 funds with older figures: up to 5 business days.

#10/ 225 years (ann.)
+7.35% NOK

as of 13 Nov 2026 · NOK class

About the figures

9 of 31 funds in the group hold no figure for the date and are not counted. 1 funds with older figures: up to 5 business days.

Comparison basis

Year to date

Comparison basis: Ranked among 18 of 31 funds · 13 left out (5 share class outside the rule, 3 missing return, 1 return as of an earlier date, 1 history too short, 3 return without a stated date) · returns as of 12 Nov 2026–13 Nov 2026

1 year

Comparison basis: Ranked among 22 of 31 funds · 9 left out (4 missing return, 2 return as of an earlier date, 3 return without a stated date) · returns as of 12 Nov 2026–13 Nov 2026

3 years (ann.)

Comparison basis: Ranked among 22 of 31 funds · 9 left out (4 missing return, 2 return as of an earlier date, 3 return without a stated date) · returns as of 12 Nov 2026–13 Nov 2026

5 years (ann.)

Comparison basis: Ranked among 22 of 31 funds · 9 left out (4 missing return, 2 return as of an earlier date, 3 return without a stated date) · returns as of 12 Nov 2026–13 Nov 2026

The positions describe historical return and are not an assessment of the fund, nor investment advice. Past performance is no guarantee of future returns. A position applies only within its own peer group and cannot be compared with positions in other peer groups.

Fund data is taken from the managers’ own reports, otherwise computed from NAV history and, as a last resort, taken from distributor listings. Not official figures; verify with the fund provider before investing.

About our data